Press Releases

Summary Toggle Arbutus to Participate in Upcoming Investor Conferences

Apr 27, 2016

Arbutus to Participate in Upcoming Investor Conferences 13.8 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in the following upcoming investor...

Read more
Summary Toggle Arbutus Presents Data from Combination Activity Studies of HBV Drug Candidates

Apr 22, 2016

Arbutus Presents Data from Combination Activity Studies of HBV Drug Candidates 21.5 KB

Additional Preclinical Combination Data to be Presented This Year Clinical Combination Studies to Begin in 2017 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 22, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic...

Read more
Summary Toggle Arbutus Announces Planned Executive Departure

Apr 21, 2016

Arbutus Announces Planned Executive Departure 15 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Patrick T. Higgins, Arbutus' Chief Business Officer has decided to leave...

Read more
Summary Toggle Arbutus Presents Data on HBV Capsid Assembly Inhibitor AB-423 at EASL 2016

Apr 14, 2016

Arbutus Presents Data on HBV Capsid Assembly Inhibitor AB-423 at EASL 2016 13.1 KB

Synergistic Antiviral Activity When Combining AB-423 With Entecavir IND Filing (or Equivalent) Expected in the Second Half of 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 14, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B...

Read more
Summary Toggle Arbutus to Present Preclinical HBV Data at EASL 2016

Mar 30, 2016

Arbutus to Present Preclinical HBV Data at EASL 2016 16.3 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EASL) selection...

Read more
Summary Toggle Arbutus Announces Year-End 2015 Financial Results

Mar 09, 2016

Arbutus Announces Year-End 2015 Financial Results 42.1 KB

Current Cash Expected to Fund Operations Into Late 2018
...

Read more
Summary Toggle Arbutus Appoints Dr. Elizabeth Howard Executive Vice President and General Counsel

Mar 08, 2016

Arbutus Appoints Dr. Elizabeth Howard Executive Vice President and General Counsel 12.9 KB

Strengthens Emphasis on Intellectual Property
...

Read more
Summary Toggle Arbutus to Participate in Upcoming Investor Conferences

Mar 03, 2016

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the company will be...

Read more
Summary Toggle Arbutus to Participate in Upcoming Investor Conferences

Feb 04, 2016

Arbutus Biopharma to Participate in Upcoming Investor Conferences 16.9 KB

...

Read more
Summary Toggle Arbutus Provides a Corporate Update and Outlines 2016 Milestones

Jan 10, 2016

Arbutus Provides a Corporate Update and Outlines 2016 Milestones 28.5 KB

Phase II Multidose Study of ARB-1467 in HBV Patients Was Initiated in 2015 Phase II Single Dose HBsAg Reduction Data Expected in 3Q16 Four HBV Products in Clinical Development by Year-End VANCOUVER, British Columbia and DOYLESTOWN, Pa., Jan. 10, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma...

Read more